Developer docs
API playgroundTry for free, no card

Search company profiles

Canonic

Full company profile

uuid002ui6c

Namestring
Canonic
Websiteurl
canonicbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Canonic is a privately-held Israeli biotech company founded in 2019 and headquartered in Rehovot, Israel. The company states that it develops medical-grade cannabis through a "revolutionary genomic approach," indicating a plant biotechnology / computational genomics product development methodology aimed at producing pharmaceutical-quality cannabis cultivars or genetic assets. The company is led by Arnon Heyman, who serves as CEO and founder, and operates with a small team of 1-10 employees, consistent with an early-stage R&D-oriented organization.

The company's go-to-market, product portfolio, customer base, partnerships, and revenue mechanics are not documented in the available data. No products, certifications, patents, distribution channels, or commercial milestones are disclosed. Canonic's website (canonicbio.com) currently displays a default cPanel hosting error page, indicating that the site is either misconfigured, recently moved, or has had an IP change — a signal that limits verification of any first-party product or commercial claims. No funding rounds, investors, or capital-raising events are recorded in the input data, leaving the company's financial runway and capitalization unverified.

Based on the available evidence, Canonic appears to be an early-stage plant-genomics venture in the medical cannabis sector, but the absence of disclosed commercial traction, funding history, product launches, and operational web presence materially constrains any deeper assessment.

Short descriptiontext

Canonic is an Israel-based, privately-held biotech company founded in 2019 that develops medical-grade cannabis using a genomic approach, operating with 1-10 employees under founder and CEO Arnon Heyman.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
medical cannabis, cannabis genomics, pharmaceutical cannabis, cannabis biotechnology, plant genomics
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Medical Cannabis Biotechnology
No data
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Canonic develops medical-grade cannabis using a genomic-based approach. The company applies genomic science to produce pharmaceutical-quality cannabis strains intended for medical applications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Medical-grade cannabis (genomic)
CategoryMedical Cannabis
Description

Genomics-based medical-grade cannabis developed for pharmaceutical use; targeted at healthcare and patient populations requiring standardized cannabis therapeutics.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Aurora Cannabis
TypeBroad incumbent
Description

Major Canadian licensed producer with a sizable medical cannabis business in multiple countries. Comparable medical-channel reach and cultivar development investment.

2Zelira Therapeutics
TypeEmerging player
Description

Clinical-stage cannabis therapeutics company focused on validated, pharma-grade products. Comparable as a small-cap medical-cannabis R&D peer with a similar profile to Canonic.

3Canopy Growth Corporation
TypeBroad incumbent
Description

One of the largest cannabis companies globally, with a medical division and significant R&D investment, including the prior acquisition of cannabis genetics firm Ebbu — directly relevant to Canonic's genomic thesis.

4Trait Biosciences
TypeDirect peer
Description

Biotechnology company focused on cannabis genetics and cannabinoid extraction IP. Comparable genomics-first, IP-led approach to medical cannabis.

5AusCann Group Holdings
TypeRegional player
Description

Australian-listed medical cannabis company developing cannabinoid pharmaceutical products for the APAC region. Comparable as a small, medically-focused cannabis R&D company outside the North American/Israeli core.

6Phylos Bioscience
TypeDirect peer
Description

Cannabis genetics and genomics company that developed a genotype library and trait-prediction platform. Closely aligned with Canonic's stated genomic differentiation.

7Front Range Biosciences
TypeDirect peer
Description

US-based cannabis and hemp genetics company using tissue culture and genomics to develop novel cultivars. Directly comparable to Canonic's genomic approach to medical-grade cannabis development.

8Cronos Group
TypeBroad incumbent
Description

Global cannabis operator with a medical and wellness focus and biotech partnerships. Comparable as a diversified incumbent with medical-grade cannabis ambitions.

9GW Pharmaceuticals (Jazz Pharmaceuticals)
TypeBroad incumbent
Description

Pioneer in pharmaceutical-grade cannabinoid medicines (e.g., Sativex, Epidiolex). Represents the established medical-cannabis-pharma benchmark Canonic aspires to.

10Tilray Brands
TypeBroad incumbent
Description

Large global cannabis operator with significant medical cannabis cultivation and distribution. A broad incumbent whose medical arm competes for the same clinical buyers Canonic targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Canonic

Medical Cannabis Biotechnologycanonicbio.com

Canonic is an Israel-based, privately-held biotech company founded in 2019 that develops medical-grade cannabis using a genomic approach, operating with 1-10 employees under founder and CEO Arnon Heyman.

What Canonic does

Canonic is a privately-held Israeli biotech company founded in 2019 and headquartered in Rehovot, Israel. The company states that it develops medical-grade cannabis through a "revolutionary genomic approach," indicating a plant biotechnology / computational genomics product development methodology aimed at producing pharmaceutical-quality cannabis cultivars or genetic assets. The company is led by Arnon Heyman, who serves as CEO and founder, and operates with a small team of 1-10 employees, consistent with an early-stage R&D-oriented organization.

The company's go-to-market, product portfolio, customer base, partnerships, and revenue mechanics are not documented in the available data. No products, certifications, patents, distribution channels, or commercial milestones are disclosed. Canonic's website (canonicbio.com) currently displays a default cPanel hosting error page, indicating that the site is either misconfigured, recently moved, or has had an IP change — a signal that limits verification of any first-party product or commercial claims. No funding rounds, investors, or capital-raising events are recorded in the input data, leaving the company's financial runway and capitalization unverified.

Based on the available evidence, Canonic appears to be an early-stage plant-genomics venture in the medical cannabis sector, but the absence of disclosed commercial traction, funding history, product launches, and operational web presence materially constrains any deeper assessment.

Canonic firmographics

Firmographics
Name
Canonic
Website
https://canonicbio.com
Company type
Private
Founded year
2019
Headcount range
1–10 employees
Short description
Canonic is an Israel-based, privately-held biotech company founded in 2019 that develops medical-grade cannabis using a genomic approach, operating with 1-10 employees under founder and CEO Arnon Heyman.
Ownership category
akta.pro rank

Where Canonic is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Markets served

Canonic business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations

Canonic product offering

Product offering

Core offering

Canonic develops medical-grade cannabis using a genomic-based approach. The company applies genomic science to produce pharmaceutical-quality cannabis strains intended for medical applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Medical-grade cannabis (genomic) Genomics-based medical-grade cannabis developed for pharmaceutical use; targeted at healthcare and patient populations requiring standardized cannabis therapeutics.

Companies that use Canonic

Customer profile

Ideal customer profiles1 record

Canonic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Canonic partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Canonic competitors and assessment

Company assessment

Broad incumbents

  • Aurora Cannabis: Major Canadian licensed producer with a sizable medical cannabis business in multiple countries. Comparable medical-channel reach and cultivar development investment.
  • Canopy Growth Corporation: One of the largest cannabis companies globally, with a medical division and significant R&D investment, including the prior acquisition of cannabis genetics firm Ebbu — directly relevant to Canonic's genomic thesis.
  • Cronos Group: Global cannabis operator with a medical and wellness focus and biotech partnerships. Comparable as a diversified incumbent with medical-grade cannabis ambitions.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in pharmaceutical-grade cannabinoid medicines (e.g., Sativex, Epidiolex). Represents the established medical-cannabis-pharma benchmark Canonic aspires to.
  • Tilray Brands: Large global cannabis operator with significant medical cannabis cultivation and distribution. A broad incumbent whose medical arm competes for the same clinical buyers Canonic targets.

Emerging players

  • Zelira Therapeutics: Clinical-stage cannabis therapeutics company focused on validated, pharma-grade products. Comparable as a small-cap medical-cannabis R&D peer with a similar profile to Canonic.

Direct peers

  • Trait Biosciences: Biotechnology company focused on cannabis genetics and cannabinoid extraction IP. Comparable genomics-first, IP-led approach to medical cannabis.
  • Phylos Bioscience: Cannabis genetics and genomics company that developed a genotype library and trait-prediction platform. Closely aligned with Canonic's stated genomic differentiation.
  • Front Range Biosciences: US-based cannabis and hemp genetics company using tissue culture and genomics to develop novel cultivars. Directly comparable to Canonic's genomic approach to medical-grade cannabis development.

Regional players

  • AusCann Group Holdings: Australian-listed medical cannabis company developing cannabinoid pharmaceutical products for the APAC region. Comparable as a small, medically-focused cannabis R&D company outside the North American/Israeli core.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

Canonic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Canonic leadership team

Management profile

Number of profiles

Profiles1 record

Canonic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Canonic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canonic

What does Canonic do?

Canonic develops medical-grade cannabis using a genomic-based approach. The company applies genomic science to produce pharmaceutical-quality cannabis strains intended for medical applications.

When was Canonic founded?

Canonic was founded in 2019. It employs 1 to 10 people.

Where is Canonic based?

Canonic is headquartered in Rehovot, Israel, in the Middle East region.

Who are Canonic's main competitors?

Broad incumbents on record are Aurora Cannabis, Canopy Growth Corporation, Cronos Group, GW Pharmaceuticals (Jazz Pharmaceuticals) and Tilray Brands. Zelira Therapeutics is listed as an emerging player. Direct peers are Trait Biosciences, Phylos Bioscience and Front Range Biosciences. AusCann Group Holdings is listed as a regional player.

Does Canonic have an API?

No public API is recorded for Canonic.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEvogene Reports First Quarter 2024 Financial ResultsEvogene Ltd. reported Q1 2024 revenue of $4.2 million, a significant increase from $0.6 million in Q1 2023, driven by licensing revenue from Lavie Bio's Corteva agreement and AgPlenus's new Bayer collaboration, while net loss improved to $3.8 million from $7.0 million year-over-year. The company ceased its Canonic subsidiary's operations, resulting in annualized savings of approximately $1.5 million, and projects 2024 cash usage (excluding Lavie Bio and Biomica) to decline 36% to $8.0 million. Casterra secured agreements with African and Brazilian castor seed growers for approximately 900 tons of seeds to fulfill existing purchase orders by end of 2024.PR NewswireCanonic Successfully Launched Six Second-Generation Cannabis Products with Higher THC and Rich Terpene ProfilesCanonic Ltd., a wholly owned subsidiary of Evogene Ltd., announced the successful launch of six second-generation hybrid cannabis products in the Israeli market, with THC levels ranging from 23% to 24.4%. The products were developed using Evogene's GeneRator AI tech-engine and proprietary genetic markers, representing a significant advancement from the company's first-generation products launched in 2021. The company expects sales growth in 2023 and plans to expand to European markets while developing third-generation products with new terpene profiles.PR NewswireCanonic Announces Professor Itamar Grotto Joining its Board of DirectorsCanonic Ltd., a wholly-owned subsidiary of Evogene Ltd., announced that Professor Itamar Grotto is joining its Board of Directors. Professor Grotto previously led the medicalization reform of cannabis in Israel as Associate Director General at the Israeli Ministry of Health and oversaw the Israeli Medical Cannabis Agency. The appointment is expected to support Canonic's development and commercialization of medical cannabis products targeting specific indications under its Precise program.PR NewswireCanonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical CannabisCanonic Ltd., a wholly-owned subsidiary of Evogene Ltd., announced positive pre-clinical study results for its medical cannabis Precise product program, conducted in Israel by Hadassah Medical Center and Migal - Galilee Research Institute. The studies identified specific cannabis varieties with anti-inflammatory and pain relief properties in both in-vitro and in-vivo models, leading to a patent application filing. Canonic plans to launch its first Precise products in Israel during 2023, followed by expansion into the European market, where the medical cannabis market is estimated to exceed €1 billion.PR NewswireCanonic Announces Pre-Launch of its First Generation Medical Cannabis Products in IsraelCanonic Ltd, a subsidiary of Evogene Ltd., announced the pre-launch of its first-generation medical cannabis products in Israel through Telepharma pharmacy. This milestone follows the approval of product files by The Israel Medical Cannabis Authority and marks the completion of Canonic's end-to-end value chain in the country. Full commercial launch is expected in 2022 as the company aims to expand into additional markets.PR NewswireEvogene Reports First Quarter 2021 Financial ResultsEvogene Ltd. reported first quarter 2021 financial results, posting a net loss of $7.1 million compared to $7.2 million in Q1 2020, while maintaining a strong consolidated cash position of approximately $70.1 million as of March 31, 2021. The company raised $27.1 million through an "At the Market Offering" during the quarter and saw a slight decrease in operating expenses to $6.3 million from $6.9 million year-over-year. Evogene's subsidiaries achieved several milestones including positive pre-clinical results for Biomica's oncology program, a distribution agreement for Canonic's medical cannabis products, and a new collaboration between Evogene's Ag-Seed division and Plastomics for insect control genes in soybeans.PR NewswireCanonic of Evogene Group and Tikun Olam (Israel)-Cannbit, sign production and distribution agreements for Canonic products in IsraelCanonic Ltd., a subsidiary of Evogene Ltd., and Tikun Olam-Cannbit Pharmaceuticals Ltd. have entered into production and distribution agreements for Canonic's medical cannabis products in Israel. Under the agreements, Tikun Olam-Cannbit will produce the products at its IMC-GMP compliant factory and distribute them through licensed pharmacies under the Canonic brand, with Canonic's first product expected to launch in 2022. The agreements support Canonic's strategy to establish a value chain from genomics to end-product using established subcontractors, while expanding Tikun Olam-Cannbit's production and service revenue streams.PR NewswireEvogene Financial Results and Earnings Announcement Schedule for the Fourth Quarter and Full Year of 2020Evogene Ltd., a computational biology company listed on NASDAQ and TASE, announced it will release its financial results for Q4 and full year 2020 on March 3rd, 2021, with a conference call scheduled for 9:00 AM Eastern time. Dr. Arnon Heyman, CEO of Evogene's medical cannabis subsidiary Canonic Ltd., will join the call to discuss Canonic's activity. Access details for the conference call via phone and webcast have been provided, with replay available through March 5th, 2021.PR NewswireCanonic Announces Signing of First Cultivation Agreement for its Medical Cannabis VarietiesCanonic Ltd., a subsidiary of Evogene Ltd., has signed its first commercial agreement with Israeli licensed medical cannabis cultivator Telcann Ltd. for plant growth services, completing the major component of its production infrastructure for medical cannabis products in Israel. The agreement enables Canonic to proceed with commercialization of its first product from the MetaYield program under its own label, expected to begin in 2022. The Israeli medical cannabis market currently has approximately 75,000 active patients consuming roughly 30 tons annually, valued at $220 million, with industry projections estimating growth to 250,000 patients by 2025.PR NewswireCanonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis AgencyCanonic, a subsidiary of Evogene Ltd., received IMC-GAP approval from the Israel Medical Cannabis Agency for the commercial operation of its propagation farm in Rehovot. This regulatory clearance allows the company to proceed with its commercialization plan, starting with delivering seedlings to third-party growers in 2021 and targeting initial sales in Israel by 2022.